Advertisement
ResearchIn-Press PreviewOncology Open Access | 10.1172/JCI176161
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Quiralte, M. in: JCI | PubMed | Google Scholar |
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Barquín, A. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Yagüe Fernández, M. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Navarro, P. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Grazioso, T. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Sevillano, E. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Rodriguez Moreno, J. in: JCI | PubMed | Google Scholar |
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Balarezo-Saldivar, A. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Peinado, H. in: JCI | PubMed | Google Scholar |
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Izquierdo, E. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Millán, C. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by López Carrasco, I. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Prieto, M. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Madurga de Lacalle, R. in: JCI | PubMed | Google Scholar |
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Fernández-Miranda, I. in: JCI | PubMed | Google Scholar
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by Ruiz-Llorente, S. in: JCI | PubMed | Google Scholar |
1Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Madrid, Spain
2Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
3Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Boadilla del Monte, Madrid, Spain
4Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
5Department of Pathological Anatomy - Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
6Faculty of Experimental Sciences, Francisco de Vitoria University, Madrid, Spain
7R&D Oncology Business Unit, Pharmacogenomic & Cell Biology Departments, Pharmamar, Colmenar Viejo, Spain
8Laboratory of Innovation in Oncology, HM Sanchinarro University Hospital, Alcala de Henares, Spain
Find articles by García-Donas, J. in: JCI | PubMed | Google Scholar
Published April 2, 2024 - More info
Cancer-derived small extracellular vesicles (sEVs) are capable of modifying tumor microenvironment and promoting tumor progression. Ovarian cancer (OvCa) is a lethal malignancy that preferentially spreads through the abdominal cavity. Thus, the secretion of such vesicles into the peritoneal fluid could be a determinant factor in the dissemination and behavior of this disease. We designed a prospective observational study to assess the impact of peritoneal fluid-derived sEVs (PFD-sEVs) in OvCa clinical outcome. For this purpose, two patient cohorts were enrolled, including OvCa cases who underwent a diagnostic or cytoreductive surgery, and non-oncological patients as controls, who underwent abdominal surgery for benign gynecological conditions. PFD-sEVs systematic extraction from surgical samples enabled us to observe significant quantitative and qualitative differences associated with cancer diagnosis, disease stage and platinum chemosensitivity. Proteomic profiling of PFD-sEVs led to the identification of molecular pathways and proteins of interest and to the biological validation of S100A4 and STX5. In addition, unsupervised analysis of PFD-sEVs proteomic profiles in high-grade serous ovarian carcinomas (HGSOC) revealed two clusters with different outcomes in terms of overall survival. In conclusion, comprehensive characterization of the PFD-sEVs content provided a prognostic value with potential implications in HGSOC clinical management.